ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On January4, 2017, Abbott Laboratories completed the acquisition
of St. Jude Medical,Inc. Beginning with the first quarter of
2017, Abbotts cardiovascular and neuromodulation (ACN) business
will include its historical Vascular Products segment and the
businesses of St. Jude Medical,Inc.
On January25, 2017, Abbott issued comparable historic revenue for
the ACN business for each quarter of 2016 and the full year in
the following three categories: Rhythm Management and Heart
Failure, Cardiovascular and Structural Heart, and
Neuromodulation.
In order to provide investors with additional detail on the ACN
business, Abbott will now be reporting ACNs sales results in the
following six categories:
Rhythm Management: This product category will
include traditional pacemakers and implantable
cardioverter-defibrillators (ICDs) and bi-ventricular cardiac
resynchronization therapy pacemakers and ICDs.
Electrophysiology: This product category will
include atrial fibrillation products.
Heart Failure: This product category will
include ventricular assist devices and the CardioMEMs HF system.
Vascular: This product category will include a
broad line of coronary, endovascular, and vessel closure devices,
diagnostic coronary imaging technology, and percutaneous heart
pumps.
Structural Heart: This product category will
include heart valve replacement and repair devices, patent
foramen ovale closure devices, and left atrial appendage closure
products.
Neuromodulation: This product category will
include spinal cord stimulation products, dorsal root ganglion
stimulation products, and deep brain stimulation products.
Please see Exhibit99.1 for comparable revenue in each product
category for each quarter of 2016 and for the full year.
The information contained in this Current Report on Form8-K and
the Exhibithereto shall not be deemed to be filed for the
purposes of Section18 of the Securities Exchange Act of 1934 (the
Exchange Act) or otherwise subject to the liabilities of that
section, nor shall it be incorporated by reference into a filing
under the Securities Act of 1933, or the Exchange Act.
Item 9.01 Financial Statements and
Exhibits
|
Exhibit No. |
Exhibit |
|
|
99.1 |
Comparable Sales by Product (furnished to Item 2.02). |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ABBOTT LABORATORIES |
||
|
Date: April 18, 2017 |
By: |
/s/ Brian B. Yoor |
|
Brian B. Yoor |
||
|
Executive Vice President, Finance |
||
|
and Chief Financial Officer |
EXHIBIT INDEX
|
Exhibit No. |
Exhibit |
|
|
99.1 |
Comparable Sales by Product (furnished |
About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products. ABBOTT LABORATORIES (NYSE:ABT) Recent Trading Information
ABBOTT LABORATORIES (NYSE:ABT) closed its last trading session up +0.64 at 43.31 with 8,068,503 shares trading hands.
